[
  {
    "question": "Influenza vaccine in MS",
    "option_a": "(SSEP): Evaluates somatosensory conduction but lacks the overall lesion sensitivity needed for MS monitoring. Option b (VEP): Assesses optic nerve conduction; useful for detecting optic neuritis but not comprehensive for MS disease activity. Option c (BSEP): Limited role in MS evaluation. Option d (MRI): Offers a comprehensive view of white matter lesions and disease activity, making it the correct and preferred modality.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an immune\u2010mediated demyelinating disorder of the central nervous system in which imaging plays a crucial role. MRI is the gold standard for diagnosing MS and monitoring its activity, while evoked potential studies (such as SSEP, VEP, and BSEP) provide supplementary information about conduction in specific neural pathways. In MS, autoreactive immune cells, primarily T lymphocytes, attack the myelin sheath of nerve fibers, leading to demyelination and the formation of plaques visible on MRI. Following events that modulate the immune system (such as vaccination), a careful evaluation with MRI may reveal new lesions or activity associated with the disease process. MS patients can experience subclinical disease activity or overt relapses. Although vaccinations like the influenza vaccine are recommended to prevent infections that could trigger MS exacerbations, monitoring disease activity with MRI remains essential, as it is more sensitive to new or enhancing lesions compared to evoked potentials. The differential diagnosis for white matter lesions includes neuromyelitis optica, small vessel ischemic disease, and other demyelinating or inflammatory disorders. MRI helps differentiate MS by showing characteristic periventricular, juxtacortical, infratentorial, and spinal cord lesions. Evoked potentials (SSEP, VEP, BSEP) may detect conduction abnormalities in specific pathways but do not offer the comprehensive lesion mapping that MRI provides. Management of MS includes immunomodulatory therapy along with symptomatic treatment. MRI is used not only to establish the diagnosis but also to monitor response to treatment and detect new disease activity\u2014especially important when evaluating the impact of interventions such as vaccinations. In pregnancy and lactation, MRI without gadolinium is generally considered safe if imaging is necessary, and influenza vaccination is recommended given the risks associated with infection. Option a (SSEP): Evaluates somatosensory conduction but lacks the overall lesion sensitivity needed for MS monitoring. Option b (VEP): Assesses optic nerve conduction; useful for detecting optic neuritis but not comprehensive for MS disease activity. Option c (BSEP): Limited role in MS evaluation. Option d (MRI): Offers a comprehensive view of white matter lesions and disease activity, making it the correct and preferred modality. 1. MRI is the most sensitive imaging tool for detecting MS lesions. 2. Influenza vaccination in MS patients helps prevent infections that might precipitate exacerbations. 3. While evoked potentials can uncover subclinical deficits, they are not substitutes for MRI in assessing overall disease burden. Recent clinical guidelines and research continue to reaffirm MRI\u2019s central role in MS diagnosis and monitoring. Moreover, current recommendations support administering the influenza vaccine to MS patients as there is no evidence linking it to increased disease activity.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Improve MS\u2013related fatigue.",
    "option_a": "(Pemoline): Previously used but now contraindicated because of its hepatotoxicity. Option b (Modafinil): Has demonstrated efficacy in multiple studies for reducing fatigue in MS. Option c (Amantadine): Also has evidence supporting modest improvements in fatigue symptoms. Option d (Dalfampridine): While it helps improve walking speed by enhancing conduction in demyelinated fibers, its benefits do not extend to alleviating fatigue.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b, c",
    "subspecialty": "Neuroimmunology",
    "explanation": "Fatigue is a common and often disabling symptom in MS, with a multifactorial origin that requires both non-pharmacologic and pharmacologic management. Pharmacologic agents such as modafinil and amantadine have been shown to provide symptomatic improvement in MS-related fatigue. The mechanism underlying MS fatigue is not entirely clear but is thought to involve disrupted neural conduction due to demyelination, inflammatory cytokine activity, and neurotransmitter imbalances. Modafinil is believed to work by enhancing wakefulness through dopaminergic and other neurotransmitter pathways, whereas amantadine may alleviate fatigue by increasing dopaminergic tone and antagonizing NMDA receptors. MS-related fatigue can significantly affect quality of life and daily functioning. The fatigue experienced in MS is often disproportionate to physical activity and may be exacerbated by sleep disturbances, depression, or side effects of medication. Pharmacologic agents like modafinil and amantadine are used after non-pharmacologic interventions (such as energy conservation techniques) have been maximized. When evaluating fatigue in MS, it is important to rule out other causes such as depression, sleep disorders (e.g., sleep apnea), anemia, and medication side effects. Utilizing fatigue scales (e.g., the Fatigue Severity Scale) helps in quantifying the severity of fatigue and guiding treatment decisions. First-line management for MS-related fatigue includes non-pharmacologic interventions\u2014such as structured exercise programs, sleep hygiene, and energy conservation strategies. Pharmacologically, modafinil and amantadine are considered first-line agents based on available evidence. In pregnancy and lactation, both modafinil and amantadine are typically used with caution due to limited safety data; non-pharmacologic strategies are preferred unless the benefit outweighs potential risks. Secondary agents like stimulants (e.g., methylphenidate) might be considered only after evaluating safety profiles in these populations. Option a (Pemoline): Previously used but now contraindicated because of its hepatotoxicity. Option b (Modafinil): Has demonstrated efficacy in multiple studies for reducing fatigue in MS. Option c (Amantadine): Also has evidence supporting modest improvements in fatigue symptoms. Option d (Dalfampridine): While it helps improve walking speed by enhancing conduction in demyelinated fibers, its benefits do not extend to alleviating fatigue. 1. Always assess for other contributing factors (like sleep disorders or depression) when managing fatigue in MS. 2. Modafinil and amantadine have the most evidence for managing MS-related fatigue. 3. Pharmacologic treatments should be tailored to the individual, with extra caution in pregnant and lactating patients. Recent studies and clinical trials reinforce the use of modafinil and amantadine for MS-related fatigue, although individual responses vary. Current guidelines underscore the importance of combining non-pharmacologic strategies with pharmacologic therapy in a personalized treatment plan, with heightened caution regarding these medications during pregnancy and lactation due to their limited safety data.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant in 10 weeks, side effect of steroids",
    "option_a": "(Spina bifida): More commonly linked to folate deficiency and specific anticonvulsants rather than corticosteroids. Option b (Premature labour): Though associated with various risk factors, it is not the most documented teratogenic effect of steroids. Option c (Cleft palate): Correct",
    "option_b": "",
    "option_c": "",
    "option_d": "(Cardiac defect): Not strongly linked to corticosteroid exposure.",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "Teratogenicity in early pregnancy is a critical concern, particularly during organogenesis. Corticosteroids, when administered during specific sensitive periods, have been associated with distinct congenital malformations. Corticosteroids can interfere with normal embryological development by affecting molecular signaling pathways. Specifically, exposure during weeks 6\u20139 of gestation\u2014the period of palatal formation\u2014can disrupt the fusion of the palatal shelves, increasing the risk of cleft palate. A pregnant patient at 10 weeks falls within the critical window where the developing embryo is vulnerable to teratogenic agents. In this period, the risk for orofacial clefts, such as cleft palate, becomes a notable concern with corticosteroid exposure. When considering teratogenic effects of medications, a differential diagnosis includes neural tube defects (e.g., spina bifida), premature labor complications, or cardiac defects. The timing of exposure relative to embryologic milestones helps in differentiating these conditions, with cleft palate being most closely linked to corticosteroid exposure during palatal fusion. In scenarios where corticosteroids are medically essential during pregnancy, the benefits must be carefully weighed against the potential teratogenic risks. When possible, using the lowest effective dose for the shortest duration is advisable. During pregnancy and lactation, alternative treatments should be considered, and if corticosteroids are necessary, enhanced fetal monitoring (including targeted ultrasound examinations) is recommended. Option a (Spina bifida): More commonly linked to folate deficiency and specific anticonvulsants rather than corticosteroids. Option b (Premature labour): Though associated with various risk factors, it is not the most documented teratogenic effect of steroids. Option c (Cleft palate): Correct \u2013 the timing and mechanism of exposure to corticosteroids during palatal development establish its association with cleft palate. Option d (Cardiac defect): Not strongly linked to corticosteroid exposure. 1. The period of weeks 6\u20139 of gestation is pivotal for palatal fusion, and exposure to teratogens during this time increases the risk of cleft anomalies. 2. Although corticosteroids have a potential teratogenic effect, the absolute risk remains low when used appropriately. 3. Risk-benefit assessment is crucial when prescribing medications during early pregnancy. Recent reviews continue to show a modest yet significant association between first\u2010trimester corticosteroid use and orofacial clefts. Current guidelines recommend cautious use of corticosteroids during pregnancy, emphasizing the minimization of dose and duration to reduce risks.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "MS lesion",
    "option_a": "(T cell): Correct",
    "option_b": "(B cell): Although B cells contribute to the pathology in MS, they are secondary in lesion initiation. Option c (Eosinophils): Not typically observed in MS lesions; their presence suggests alternative diagnoses like neuromyelitis optica. Option d (Neutrophils): Generally not involved in the chronic autoimmune process of MS.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuroimmunology",
    "explanation": "MS lesions are characterized by focal areas of inflammation, demyelination, and subsequent gliosis in the central nervous system. Understanding the cellular composition of these lesions is essential to grasp the pathogenesis of MS. The inflammatory process in MS is primarily mediated by autoreactive T lymphocytes (predominantly CD4+ T cells) that cross the blood-brain barrier. These cells instigate an immune cascade that leads to oligodendrocyte injury and demyelination. Although B cells play a contributory role (especially in antibody production), T cells remain the primary drivers of lesion initiation and propagation. The T cell\u2013mediated attack on myelin results in demyelinated plaques that are responsible for the neurological deficits seen in MS, such as visual disturbances, motor weakness, and sensory impairments. The predominance of T cells within these lesions underlies the rationale for therapies that modulate T cell responses. Differential diagnosis includes neuromyelitis optica spectrum disorders (characterized by a different immune profile, often with eosinophils and a prominence of B-cell mediated pathology), acute disseminated encephalomyelitis, and other inflammatory or infectious diseases of the CNS. Histopathological examination remains the gold standard for identifying the cellular constituents of MS lesions. Management of MS involves the use of disease-modifying therapies (DMTs) that primarily aim to reduce T cell\u2013mediated inflammation. First-line DMTs include agents like interferon-beta and glatiramer acetate. In cases where more aggressive treatment is warranted, second-line therapies (targeting both T and B cells) may be employed. Pregnancy and lactation considerations require careful selection of DMTs, with many first-line agents being contraindicated or used with caution. Pre-pregnancy counseling and treatment planning are critical. Option a (T cell): Correct \u2013 T cells are the primary mediators in the formation of MS lesions. Option b (B cell): Although B cells contribute to the pathology in MS, they are secondary in lesion initiation. Option c (Eosinophils): Not typically observed in MS lesions; their presence suggests alternative diagnoses like neuromyelitis optica. Option d (Neutrophils): Generally not involved in the chronic autoimmune process of MS. 1. The hallmark of MS lesion is the predominance of T cell\u2013mediated inflammation. 2. Immunomodulatory therapies targeting T cells have been the mainstay of MS management. 3. Accurate identification of the cellular profile aids in differentiating MS from other CNS inflammatory disorders. Recent research underscores the complex interplay between T cells and B cells in MS, yet the central role of T cells in initiating lesions remains. Updated clinical guidelines continue to emphasize T cell modulation as a cornerstone of MS therapy, with newer agents further refining the balance between efficacy and safety, especially in special populations such as pregnant patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Red flag in MS",
    "option_a": "(Bilateral INO) is a known brainstem manifestation in MS and supports the diagnosis rather than being a red flag. Option b (Extensive transverse myelitis) is atypical for MS since spinal lesions in MS are usually short (<3 vertebral segments), making extensive TM a red flag; however, compared to the persistence of enhancement >3 months, option c is a more definitive red flag. Option c (Enhancing lesion >3 months) is correct because prolonged enhancement is not consistent with typical MS lesion evolution.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an autoimmune demyelinating condition of the central nervous system, characterized by episodes of neurologic dysfunction with evidence of dissemination in time and space. In imaging, certain features are expected, and deviations from these may be considered 'red flags' that prompt consideration of alternative diagnoses. MS lesions result from inflammatory demyelination with breakdown of the blood\u2013brain barrier, leading to gadolinium enhancement on MRI. Typically, gadolinium enhancement lasts about 4\u20136 weeks, reflecting active inflammation. Persistence of enhancement beyond 3 months is atypical and raises concerns for other pathology such as chronic active lesions, neoplasms, or alternative inflammatory processes. Clinical manifestations of MS usually follow a relapsing\u2010remitting course with distinct episodes of neurological deficits. An imaging red flag, like an enhancing lesion that persists far longer than expected, can prompt re-evaluation of the diagnosis if clinical features do not match the typical MS course. When evaluating suspected MS, clinicians use MRI to document lesion dissemination in time and space. Differential diagnoses include neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody associated disease, chronic inflammatory conditions, and even neoplastic processes. Persistent enhancement should initiate further investigations such as repeat imaging, cerebrospinal fluid analysis, or even tissue biopsy if indicated. Standard MS management involves disease-modifying therapies (DMTs) such as interferon-beta, glatiramer acetate, or newer agents for active or progressive disease. However, if red flags (like an enhancing lesion >3 months) are identified, further diagnostic work-up is needed before initiating or altering therapy. In contexts such as pregnancy, where imaging modalities and treatment choices must be balanced against fetal risks, careful multidisciplinary assessment is crucial. Option a (Bilateral INO) is a known brainstem manifestation in MS and supports the diagnosis rather than being a red flag. Option b (Extensive transverse myelitis) is atypical for MS since spinal lesions in MS are usually short (<3 vertebral segments), making extensive TM a red flag; however, compared to the persistence of enhancement >3 months, option c is a more definitive red flag. Option c (Enhancing lesion >3 months) is correct because prolonged enhancement is not consistent with typical MS lesion evolution. 1) In MS, gadolinium enhancement usually lasts 4\u20136 weeks; persistence >3 months is abnormal. 2) Always correlate clinical findings with imaging to ensure the diagnosis is consistent. 3) Red flags should trigger additional investigation for alternative or coexisting conditions. Recent studies confirm that the typical timeline for lesion enhancement in MS is around 4\u20136 weeks. Chronic enhancement suggests an atypical process and has led to recommendations for additional diagnostic work-up when encountered, especially when clinical features are inconsistent with typical MS. Research continues into chronic active lesions and their implications for treatment.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Multiple courses of corticosteroids during pregnancy have been most associated with which of the following fetal complications?",
    "option_a": "decreased vaccine responsiveness",
    "option_b": "hepatotoxicity",
    "option_c": "low birth weight",
    "option_d": "lymphopenia",
    "option_e": "pancytopenia",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple courses of corticosteroids during pregnancy are sometimes needed to manage exacerbations in conditions like MS or other inflammatory conditions. However, the potential fetal risks have been studied extensively. The concern centers on the impact of repeated courses on fetal growth and development. Corticosteroids cross the placenta, and while a single course (typically betamethasone or dexamethasone) is beneficial for fetal lung maturation, multiple courses may have systemic effects on the fetus. The proposed mechanism for low birth weight includes possible interference with normal fetal growth pathways and timing of maturation, resulting in growth restriction. In clinical practice, antenatal corticosteroids are administered to enhance fetal lung maturity in the event of preterm labor. However, multiple courses have been linked in some studies to lower birth weights and reduced head circumference, although the benefits in preventing respiratory distress must be carefully weighed against these risks. When evaluating fetal wellbeing after maternal corticosteroid administration, clinicians monitor growth parameters via ultrasound. Differential adverse outcomes considered include alterations in metabolism or immune function, but consistent data points most reliably to low birth weight as the key complication with multiple courses. Current guidelines recommend a single course of antenatal corticosteroids for women at risk of preterm delivery. Repeat or rescue courses should be administered only when the benefit outweighs the potential risk, with close monitoring of fetal growth. In pregnancy and lactation, the lowest effective dose and minimal courses should be used. The balance between preventing neonatal respiratory distress syndrome and avoiding fetal growth restriction must be carefully considered. Option A (decreased vaccine responsiveness) is not a recognized fetal complication of corticosteroid therapy. Option B (hepatotoxicity) is not typically associated with corticosteroid use in pregnancy. Option C (low birth weight) is correct, as multiple courses have been associated with a modest but significant reduction in birth weight. Option D (lymphopenia) and Option E (pancytopenia) are not typically described as fetal complications related to multiple courses of corticosteroids. 1) A single course of antenatal corticosteroids is the standard, with repeat courses used sparingly. 2) Low birth weight is the most consistently reported complication with multiple courses. 3) Fetal growth should be monitored closely when additional courses are given. Recent guidelines from obstetric societies recommend caution with repeated courses of corticosteroids due to the potential risk of fetal growth restriction. Meta-analyses and longitudinal studies continue to support that while short-term neonatal outcomes may be improved, there is a modest association with lower birth weight. The decision to use additional courses is made on a case-by-case basis, weighing neonatal lung benefits against potential growth impacts.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "TM, NL brain MRI, risk of MS",
    "option_a": "(10%) is correct. Longitudinal studies indicate that patients with TM and a normal brain MRI have approximately a 10% risk of converting to MS. Option b (30%), Option c (60%), and Option d (70%) significantly overstate the risk and are more reflective of patients with abnormal brain MRI findings or additional risk factors.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuroimmunology",
    "explanation": "Transverse myelitis (TM) is an inflammatory process affecting the spinal cord. In some cases, TM may be the initial demyelinating event. An important prognostic consideration is the risk of progression to multiple sclerosis (MS), which is influenced by findings on brain MRI. In MS, dissemination in space is typically evident on brain MRI through demyelinating lesions. When a patient with TM has a normal brain MRI, it suggests that the inflammatory process is isolated to the spinal cord, thus lowering the risk for MS. Studies have shown that the presence or absence of brain lesions is a key predictor for future conversion to MS. Patients who present with TM usually experience sudden onset of motor, sensory, and autonomic dysfunction. The absence of typical MS brain lesions correlates with a lower likelihood of additional subclinical demyelinating events occurring elsewhere in the CNS, thereby reducing the risk of a full-blown MS diagnosis. In evaluating TM, it is essential to perform a comprehensive MRI of the brain and spinal cord. Differential diagnoses include NMOSD, MOG-antibody associated disease, and idiopathic TM. The absence of brain lesions helps differentiate isolated TM from MS, where multiple lesions are typically present. Acute management of TM typically involves high-dose intravenous corticosteroids. If there is no evidence of MS (i.e., normal brain MRI) and clinical recovery is adequate, long-term disease-modifying therapies are not immediately indicated. During pregnancy and lactation, high-dose steroids remain the treatment for acute inflammatory events with caution, and the decision to start longer-term therapies is individualized based on risk-benefit assessments. Option a (10%) is correct. Longitudinal studies indicate that patients with TM and a normal brain MRI have approximately a 10% risk of converting to MS. Option b (30%), Option c (60%), and Option d (70%) significantly overstate the risk and are more reflective of patients with abnormal brain MRI findings or additional risk factors. 1) A normal brain MRI in the setting of TM is associated with a lower risk of developing MS. 2) The McDonald criteria rely heavily on MRI findings for the diagnosis of MS. 3) Longitudinal follow-up with serial imaging is important for early detection of new lesions. Current evidence from multiple longitudinal studies confirms that the absence of brain lesions in patients presenting with TM is associated with a conversion risk to MS of approximately 10%. These findings guide clinician decision-making regarding monitoring and long-term treatment strategies.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_35.png"
  },
  {
    "question": "Transverse myelitis, MRI: multiple enhancing lesions in brain & spinal cord",
    "option_a": "(CIS) is incorrect because CIS refers to a solitary demyelinating event without evidence of widespread lesions. Option b (MS) is unlikely given that MS typically shows spinal lesions that are shorter in extent and different in morphology. Option c (NMO) is correct because the presence of LETM and multiple enhancing lesions in both the brain and spinal cord is highly suggestive of neuromyelitis optica. Option d (RIS) is not applicable in a symptomatic patient with clear clinical and radiographic findings.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "In the evaluation of demyelinating diseases, the pattern and distribution of lesions on MRI are critical for diagnosis. Transverse myelitis with multiple enhancing lesions in both the brain and spinal cord suggests a disseminated inflammatory process that is not typical of a single event such as Clinically Isolated Syndrome (CIS) or Radiologically Isolated Syndrome (RIS). Neuromyelitis optica (NMO), or NMOSD, is an autoimmune astrocytopathy primarily mediated by antibodies against aquaporin-4 (AQP4). It is characterized by severe attacks of optic neuritis and transverse myelitis, often with longitudinally extensive spinal cord lesions (involving 3 or more vertebral segments). Unlike MS, NMO lesions are typically larger, centrally located, and can involve both the brain and spinal cord. Clinically, patients with NMO present with severe visual loss from optic neuritis and motor, sensory, or autonomic dysfunction from transverse myelitis. The presence of multiple enhancing lesions in both the brain and spinal cord on MRI, along with a clinical picture of transverse myelitis, is more suggestive of NMO than MS, particularly when lesions extend over long segments in the spinal cord. Diagnosis of demyelinating disorders involves correlating clinical findings with imaging and laboratory tests. Differential diagnoses include CIS (a single demyelinating event), MS (which typically has shorter spinal lesions and ovoid brain lesions), and RIS (incidental findings without clinical symptoms). The presence of LETM and AQP4 antibody positivity strongly favors NMO. Testing for AQP4-IgG antibodies is critical for confirming NMOSD. Acute management of NMOSD involves high-dose intravenous corticosteroids, often followed by plasma exchange if there is an inadequate response. For long-term prevention of relapses, immunosuppressive therapies (e.g., rituximab, mycophenolate mofetil, azathioprine) are recommended. In pregnant or lactating patients, treatment decisions must balance maternal disease control with fetal safety; for example, some immunosuppressants are contraindicated or used with extreme caution during pregnancy. Option a (CIS) is incorrect because CIS refers to a solitary demyelinating event without evidence of widespread lesions. Option b (MS) is unlikely given that MS typically shows spinal lesions that are shorter in extent and different in morphology. Option c (NMO) is correct because the presence of LETM and multiple enhancing lesions in both the brain and spinal cord is highly suggestive of neuromyelitis optica. Option d (RIS) is not applicable in a symptomatic patient with clear clinical and radiographic findings. 1) LETM (involvement of \u22653 vertebral segments) is highly characteristic of NMOSD. 2) AQP4-IgG antibody testing is essential for confirming the diagnosis of NMO. 3) Differentiating NMOSD from MS is crucial as treatment strategies differ significantly. Recent guidelines and research have emphasized early and aggressive treatment in NMOSD to prevent irreversible neurological damage. New therapeutic agents (e.g., eculizumab) are emerging for NMOSD, and current international consensus criteria aid in improving diagnostic accuracy. Special considerations in pregnancy are highlighted in updated guidelines, stressing the need for tailored immunosuppressive regimens.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Safe for pregnant MS",
    "option_a": "(Fingolimod) is incorrect due to its known teratogenic risk and contraindication in pregnancy. Option B (Glatiramer Acetate) is correct as it is safe and widely used during pregnancy. Option C (Teriflunomide) is incorrect because of its established teratogenicity. Option D (Dimethyl Fumarate) is correct, given its relatively reassuring pregnancy data despite more limited experience compared to GA.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B, D",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) patients who are pregnant or planning pregnancy require special consideration regarding the safety of disease\u2010modifying therapies (DMTs). The core concept is to maintain disease control while minimizing teratogenic risks. Agents such as Glatiramer Acetate (GA) and Dimethyl Fumarate (DF) have a more favorable pregnancy safety profile compared with others like fingolimod and teriflunomide. Glatiramer Acetate works by acting as a myelin basic protein mimic and shifting the immune response toward a regulatory profile without significant systemic immunosuppression. Dimethyl Fumarate activates the Nrf2 pathway, which contributes to anti\u2010inflammatory and cytoprotective effects. In contrast, fingolimod modulates sphingosine-1-phosphate receptors and can adversely affect fetal heart and vascular development, while teriflunomide interferes with pyrimidine synthesis and is associated with teratogenicity. In clinical practice, pregnant women with MS or those planning pregnancy are best managed with agents having extensive safety data. GA has long been used during pregnancy with no increased risk of miscarriage or congenital anomalies, whereas DF has limited but reassuring data. The potential risks associated with fingolimod and teriflunomide (including fetal malformations) necessitate their discontinuation prior to conception. When evaluating MS treatment in pregnancy, clinicians review patient history, disease activity, and safety profiles from pregnancy registries and post-marketing surveillance. Differential consideration includes choosing between first\u2010line therapies (like GA, interferon-beta) that have established safety profiles versus higher efficacy but teratogenic therapies. Current guidelines recommend that women with MS who plan pregnancy should ideally be switched to a DMT with an established safety record (e.g., GA). First-line management is with GA; DF can be considered as an alternative in patients with less active disease, though more data are required. Second-line agents (fingolimod and teriflunomide) are contraindicated. For lactating mothers, GA also has a favorable profile. Counseling before conception is critical, and if switching therapies, an adequate washout period is required (especially for teriflunomide and fingolimod). Option A (Fingolimod) is incorrect due to its known teratogenic risk and contraindication in pregnancy. Option B (Glatiramer Acetate) is correct as it is safe and widely used during pregnancy. Option C (Teriflunomide) is incorrect because of its established teratogenicity. Option D (Dimethyl Fumarate) is correct, given its relatively reassuring pregnancy data despite more limited experience compared to GA. 1. Glatiramer Acetate has an extensive safety record in pregnancy and is considered a first\u2010line option. 2. Teriflunomide requires an accelerated elimination procedure before conception due to its teratogenic potential. 3. Fingolimod\u2019s mechanism includes modulation of the S1P receptor, posing fetal risks. Recent reviews and registry data (including those from the National MS Society and EMA guidelines) support the use of GA in pregnant patients. While DF has less longitudinal data, emerging studies suggest it is relatively safe. Updated guidelines continue to stress the need to avoid fingolimod and teriflunomide in women planning pregnancy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with DM type 1, came with Hx of stiffness, what is the antibody",
    "option_a": "(Anti",
    "option_b": "(Anti",
    "option_c": "(Anti",
    "option_d": "(Anti",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Stiff-Person Syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive rigidity and painful muscle spasms. It is frequently associated with other autoimmune diseases, particularly type 1 diabetes mellitus. The hallmark of SPS is the presence of autoantibodies against glutamic acid decarboxylase (GAD), the enzyme responsible for synthesizing gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. The reduction in GABA leads to unopposed muscle activity and stiffness. Patients typically present with insidious onset of fluctuating muscle stiffness, most notably in the axial muscles, along with episodic painful spasms. There is a well-documented association between SPS and type 1 diabetes, reinforcing the autoimmune basis of the disease. Diagnosis is based on clinical presentation, electrophysiological studies, and serologic testing for anti-GAD antibodies. Differential diagnoses include tetanus, dystonia, and other forms of autoimmune encephalitis. The presence of high anti-GAD titers strongly supports the diagnosis of SPS. First-line management involves symptomatic therapy using benzodiazepines (e.g., diazepam) and baclofen. Immunomodulatory treatments such as intravenous immunoglobulin (IVIG) are considered in refractory cases. In pregnant or lactating patients with SPS, treatment choices must carefully balance maternal benefits with fetal risks; benzodiazepines should be used with caution, and IVIG is generally considered safe during pregnancy. Option A (Anti-NMDA antibodies) is incorrect as these are seen in anti-NMDA receptor encephalitis, not SPS. Option B (Anti-GAD antibodies) is correct and is the recognized autoimmune marker in SPS. Option C (Anti-GABA antibodies) is not a recognized entity in this context. Option D (Anti-AMPA antibodies) is associated with limbic encephalitis, not with the stiffness seen in SPS. 1. SPS is strongly associated with type 1 diabetes, underscoring its autoimmune nature. 2. Anti-GAD antibodies are the serologic hallmark of SPS. 3. Early recognition and treatment can significantly improve quality of life. Recent studies and consensus guidelines have reinforced the role of anti-GAD antibodies in diagnosing SPS. Immunotherapies such as IVIG have shown efficacy in randomized trials, and current research continues to explore additional targeted immunomodulatory therapies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "MS patient who is receiving natalizumab and developed PML, what to do? (stopping natalizumab was not in the choices)",
    "option_a": "Start plex",
    "option_b": "IVIG",
    "option_c": "Steroids",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a high-efficacy anti-inflammatory agent used in the treatment of relapsing-remitting multiple sclerosis (RRMS). Its use, however, is associated with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and serious opportunistic infection of the central nervous system caused by JC virus. Natalizumab works by preventing lymphocyte migration across the blood-brain barrier, thereby reducing inflammation. This same mechanism, however, predisposes patients to PML by impairing immune surveillance in the CNS, allowing JC virus reactivation and demyelination. Patients on natalizumab who develop new or worsening neurological deficits must be evaluated promptly for PML. The clinical picture often includes cognitive decline, motor weakness, visual changes, and other focal deficits. MRI findings and JC virus PCR in cerebrospinal fluid are key to diagnosis. The differential diagnosis for new neurological symptoms in a natalizumab-treated patient includes MS relapse, PML, and immune reconstitution inflammatory syndrome (IRIS). MRI and CSF studies play central roles in distinguishing PML from these conditions. The primary management step in natalizumab-associated PML is the rapid removal of natalizumab from circulation. Since discontinuation of the drug is presumed (though not an option in this question), the next step is plasma exchange (PLEX) to hasten drug clearance, reconstituting immune surveillance in the CNS. This is considered a first-line intervention. In cases where immune reconstitution inflammatory syndrome (IRIS) develops, steroids may be used as a second-line therapy. In pregnant or lactating patients, similar principles apply; however, extra caution is needed given the limited safety data regarding PLEX in pregnancy, and the maternal-fetal risk must be balanced against the severity of PML. Option A (Start PLEX) is correct because plasma exchange is the standard approach to accelerate natalizumab removal in PML. Option B (IVIG) is not standard for PML management. Option C (Steroids) may be reserved for managing IRIS rather than as an initial treatment for PML. 1. Early detection of PML in natalizumab-treated MS patients is pivotal. 2. Plasma exchange is the key intervention to speed up natalizumab clearance from the bloodstream. 3. Always monitor for signs of IRIS following immune reconstitution. Recent literature and updated guidelines from neurology societies emphasize the use of plasma exchange in natalizumab-associated PML. Ongoing research is focused on optimizing the timing and management of IRIS following PLEX.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of opsoclonus myoclonus with breast cancer",
    "option_a": "Anti RI",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic neurological disorder. It is characterized by rapid, multidirectional eye movements (opsoclonus) and myoclonic jerks, often associated with underlying malignancies such as breast cancer. The syndrome is thought to result from an autoimmune response where antibodies generated against tumor antigens cross-react with neuronal antigens. Anti-Ri antibodies (also known as anti-neuronal nuclear antibody type 2) are commonly implicated in OMS associated with breast cancer. Patients typically present with chaotic, multidirectional eye movements along with involuntary muscle jerks. In a patient with a known history of breast cancer, the presence of these symptoms strongly suggests a paraneoplastic syndrome mediated by anti-Ri antibodies. The differential diagnosis for opsoclonus-myoclonus includes viral encephalitis, metabolic disturbances, and other paraneoplastic syndromes. Antibody testing (especially for anti-Ri) combined with neuroimaging and clinical correlation is key to confirming the diagnosis. The mainstay of treatment is addressing the underlying malignancy along with immunotherapy (e.g., steroids, IVIG, plasmapheresis) to modulate the autoimmune response. In pregnancy, treatment strategies require careful balance; oncologic treatments may necessitate modification to protect fetal health, and immunotherapies must be chosen with safety profiles in mind. Option A (Anti-Ri) is correct because anti-Ri antibodies are the classic marker seen in paraneoplastic OMS associated with breast cancer. The absence of alternative options underscores this as the key identifiable antibody in this scenario. 1. Opsoclonus-myoclonus syndrome can be an early indicator of an underlying malignancy, particularly breast cancer. 2. Anti-Ri antibodies are highly associated with paraneoplastic OMS. 3. Early recognition and treatment of the underlying cancer can significantly influence outcomes. Current research supports the role of anti-Ri antibodies as a diagnostic marker for OMS in patients with breast cancer. Recent guidelines emphasize early cancer screening and immunotherapy in managing paraneoplastic neurological syndromes.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of SCLC with peripheral neuropathy",
    "option_a": "Anti Hu",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Small cell lung cancer (SCLC) is notorious for its paraneoplastic syndromes. One of the most common paraneoplastic neurologic syndromes associated with SCLC involves a subacute peripheral neuropathy linked to anti-neuronal antibodies, particularly anti-Hu antibodies. Anti-Hu antibodies (also known as ANNA-1) are directed against neuronal antigens expressed in both the tumor (SCLC) and the nervous system. The immune response mistakenly attacks the dorsal root ganglia and peripheral nerves, leading to sensory neuropathy. This autoimmune cross-reactivity is the underlying mechanism of the paraneoplastic neurological syndrome. Patients with SCLC may present with symptoms such as numbness, tingling, and pain due to peripheral neuropathy. The subacute onset of these symptoms in the context of known or suspected SCLC should raise suspicion for a paraneoplastic syndrome mediated by anti-Hu antibodies. Diagnosis involves a detailed clinical history and examination, electrophysiologic studies (nerve conduction studies and electromyography), and serologic testing for onconeural antibodies. Imaging studies, such as CT or PET scans, are then used to identify or stage the underlying malignancy. Differential diagnoses include idiopathic inflammatory neuropathies, toxic neuropathies, and metabolic neuropathies. Management is two-fold: treat the underlying malignancy (SCLC) and immunomodulate the autoimmune process. First-line treatment focuses on chemotherapy and radiation for the cancer; studies suggest that early treatment may reduce further neurological damage. Immunotherapies (e.g., IV corticosteroids, IV immunoglobulins, or plasmapheresis) can be considered, although responses are variable. Pregnancy and lactation considerations are less relevant given the typical patient demographic for SCLC, but if encountered, a multidisciplinary approach is required to balance oncologic and maternal-fetal risks. Option A (Anti-Hu) is correct because it is the well-known antibody associated with paraneoplastic peripheral neuropathy in the context of SCLC. Other options (not provided) would not fit the classic paraneoplastic antibody profile seen in this setting. 1. Anti-Hu antibodies are highly associated with sensory neuronopathies in patients with SCLC. 2. Early identification of paraneoplastic syndromes can prompt earlier cancer detection and treatment. 3. Paraneoplastic neurologic syndromes are immune-mediated and often require management of both the cancer and the autoimmune process. Recent literature continues to support the role of anti-Hu antibodies in diagnosing paraneoplastic syndromes, and emerging research is exploring targeted immunotherapies. Current guidelines emphasize prompt oncologic management to improve overall patient outcomes.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "MS patient who is receiving natalizumab and developed PML, what to do?",
    "option_a": "Stop natalizumab",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a monoclonal antibody used in the treatment of multiple sclerosis (MS) that works by inhibiting leukocyte adhesion and migration across the blood-brain barrier. One of its rare, but serious, adverse effects is the development of progressive multifocal leukoencephalopathy (PML), a demyelinating disease caused by reactivation of the JC virus. Natalizumab\u2019s mechanism of blocking \u03b14-integrin decreases immune surveillance within the central nervous system, which can allow dormant JC virus to reactivate. This leads to infection of oligodendrocytes, causing widespread demyelination and the clinical syndrome of PML. Patients on natalizumab who develop new and often rapidly progressive neurological deficits (e.g., motor weakness, visual changes, cognitive impairment) should be evaluated for PML. Imaging typically reveals multifocal demyelinating lesions, and CSF analysis with PCR for JC virus confirms the diagnosis. The diagnostic workup for suspected PML includes brain MRI (which may show T2 hyperintense lesions with or without contrast enhancement), CSF analysis for JC virus DNA by PCR, and clinical correlation with neurological deficits. Differential diagnoses include MS relapse, other opportunistic infections, and acute disseminated encephalomyelitis. Immediate management requires discontinuation of natalizumab. First-line treatment involves removing the drug from the circulation with plasma exchange (PLEX) to accelerate clearance. Supportive care and management of immune reconstitution inflammatory syndrome (IRIS), which can occur following clearance, are also critical. In pregnant or lactating women, the decision to stop natalizumab must be balanced with the risk of MS relapse; however, the development of PML necessitates cessation irrespective of pregnancy due to the high mortality risk associated with PML. Option A (Stop natalizumab) is correct as it represents the immediate required action upon suspicion or diagnosis of PML. Other options (if provided) that might delay discontinuation risk worsening of the condition. 1. Natalizumab is highly effective for MS but carries a risk of PML, especially in JC virus positive individuals. 2. Early signs of new neurological deficits in patients on natalizumab mandate prompt evaluation for PML. 3. Rapid drug clearance via PLEX is recommended to mitigate ongoing immunosuppression in PML. Recent guidelines and consensus statements continue to underscore the importance of immediate natalizumab discontinuation and initiation of PLEX in suspected cases of PML. Ongoing studies are investigating optimal management strategies for IRIS following natalizumab clearance.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of a male patient with unilateral optic neuritis and brain MRI showed 3 supracortical (yes supra) lesions. He has no history of any symptoms before",
    "option_a": "CIS",
    "option_b": "MS",
    "option_c": "Optic neuritis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "A clinically isolated syndrome (CIS) is defined as a first episode of neurological symptoms that lasts at least 24 hours and is attributable to inflammation or demyelination in the central nervous system. In patients presenting with optic neuritis and MRI findings of demyelinating lesions, CIS is considered a high-risk state for the development of multiple sclerosis (MS). The underlying process in CIS involves focal areas of immune-mediated demyelination. Even if the clinical presentation is limited (e.g., optic neuritis), MRI may reveal additional subclinical demyelinating lesions in the brain, underscoring the widespread nature of the pathology. Unilateral optic neuritis is a common initial presentation in demyelinating diseases. The presence of three supracortical lesions (a pattern frequently observed in MS) in a patient with optic neuritis indicates dissemination in space. However, because there is only one clinical episode, the diagnosis remains CIS until further episodes or evidence of dissemination in time occur. Diagnosis of CIS involves correlating the clinical history with MRI findings. The McDonald criteria are used to assess dissemination in space and time. Differential diagnoses include isolated optic neuritis, neuromyelitis optica spectrum disorder (typically associated with anti-AQP4 antibodies), and other causes of white matter lesions such as small vessel ischemic disease. Ancillary testing, including CSF analysis (oligoclonal bands), can help in the prognostication toward MS. Acute management of optic neuritis typically involves high-dose corticosteroids to reduce inflammation. Disease-modifying therapies (DMTs) may be considered in patients with CIS who have high-risk features (like multiple lesions on MRI) to delay progression to MS. In pregnant or lactating women, treatment decisions require weighing the risks, but high-dose steroids are generally considered safe in the short term, while many DMTs are contraindicated or require careful use. Option A (CIS) is correct because the patient has experienced a single clinical episode (optic neuritis) with radiological evidence of additional demyelinating lesions. Option B (MS) would require evidence of dissemination in time, which is not yet fulfilled in this clinical scenario. Option C (isolated optic neuritis) would ignore the significant MRI findings. 1. The presence of silent MRI lesions in a patient with optic neuritis increases the risk of conversion to MS. 2. CIS is the term used for a first demyelinating event with supportive radiologic evidence. 3. Early intervention with steroids may improve recovery from optic neuritis, though the long\u2010term benefit on MS conversion remains a topic of study. Recent updates to the McDonald criteria have improved early diagnosis by incorporating MRI findings of dissemination in space, even at the initial presentation. There is ongoing research into early DMT initiation in CIS with high-risk features to delay or prevent progression to MS.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_18.png"
  },
  {
    "question": "Scenario of miller fisher and asked about the antibody (two questions)",
    "option_a": "GQ1B",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Miller Fisher syndrome (MFS) is a rare variant of Guillain\u2013Barr\u00e9 syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia. The condition is immune-mediated and often follows an infectious trigger. The pathogenesis of MFS is related to the production of autoantibodies that cross-react with gangliosides present in the peripheral nerves. Anti-GQ1b antibodies are most closely associated with MFS and are thought to damage nerve terminals, particularly those involved in ocular motor control. Patients with MFS typically present with ophthalmoplegia (eye movement abnormalities), ataxia (uncoordinated movements), and diminished or absent deep tendon reflexes. The presence of anti-GQ1b antibodies in the serum is highly supportive of the diagnosis. Diagnosis is based on clinical presentation supported by serologic testing for anti-GQ1b antibodies. Additional supportive tests include CSF analysis, which often shows albuminocytologic dissociation, and nerve conduction studies. Differential diagnoses include other forms of Guillain\u2013Barr\u00e9 syndrome, brainstem encephalitis, and myasthenia gravis, which have differing clinical and diagnostic features. The mainstay of treatment for MFS is supportive care, which may include intravenous immunoglobulin (IVIG) or plasmapheresis in more severe cases. Most patients recover well over weeks to months. In the context of pregnancy and lactation, IVIG is generally considered safe and is the preferred treatment option, whereas plasmapheresis, although effective, may require careful consideration and monitoring. Option A (GQ1B) is correct because anti-GQ1b antibodies are highly specific for Miller Fisher syndrome. Other options (if they were provided) would not have the same established diagnostic association with MFS. 1. The triad of ophthalmoplegia, ataxia, and areflexia is the hallmark of MFS. 2. Anti-GQ1b antibodies are present in over 90% of patients with MFS and serve as a key diagnostic marker. 3. MFS has a generally favorable prognosis with appropriate supportive treatment. Recent studies continue to reaffirm the association between anti-GQ1b antibodies and Miller Fisher syndrome. Updated guidelines recommend IVIG as a first-line treatment with plasmapheresis as an alternative in cases where IVIG is contraindicated or ineffective, with research ongoing about optimizing treatment protocols in special populations including pregnant patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of stiff person syndrome and DM1, what is the antibody?",
    "option_a": "anti GAD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Stiff person syndrome (SPS) is a rare, autoimmune neurologic disorder characterized by progressive rigidity, stiffness, and painful muscle spasms. It is frequently associated with other autoimmune conditions, including type 1 diabetes mellitus (DM1). The disease is primarily linked to antibodies against glutamic acid decarboxylase (anti\u2010GAD), an enzyme involved in the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Anti-GAD antibodies reduce the synthesis of GABA, leading to decreased inhibitory signaling within the central nervous system. This disinhibition results in continuous motor unit activity, producing the characteristic stiffness and spasms. Research has demonstrated that the autoimmune destruction or interference with GABAergic interneurons underlies the pathogenesis of SPS, with many patients also exhibiting markers of other autoimmune disorders such as DM1. Patients typically present with progressive axial rigidity, painful muscle spasms that may be triggered by sudden stimuli or emotional stress, and abnormal posturing. The co-existence of DM1 further supports an autoimmune etiology, with anti-GAD antibodies reinforcing the diagnosis. Electrophysiological studies often demonstrate continuous motor unit activity, and antibody testing corroborates the clinical suspicion. Diagnosis is based on clinical findings, confirmed by serologic detection of anti-GAD antibodies. Electromyography (EMG) can show continuous motor unit activity. Differential diagnoses include other causes of spasticity such as tetanus, extrapyramidal disorders, and psychogenic movement disorders. The presence of DM1 and a positive anti-GAD assay strongly favors SPS. First-line treatment includes symptomatic management with benzodiazepines (e.g., diazepam) and baclofen to alleviate muscle rigidity and spasms. For immunomodulatory treatment, intravenous immunoglobulin (IVIg) or plasmapheresis can be considered in moderate to severe cases. In refractory disease or those with severe disability, rituximab may be used. Pregnancy and lactation considerations: Benzodiazepines and baclofen are generally category C, and while IVIg is often considered safe, decisions should be individualized. The risk-benefit ratio must be discussed with the patient when initiating immunomodulatory therapies during pregnancy or lactation. Option A (anti-GAD) is correct because anti-GAD antibodies are the hallmark of the disease in up to 60\u201380% of patients. Other options (if provided) would likely include antibodies not associated with SPS (such as anti-amphiphysin, which is seen in some paraneoplastic cases, or antibodies unrelated to DM1) and are therefore incorrect in this context. 1. Always consider SPS in patients with progressive stiffness and spasms, especially with a history of autoimmune diseases like DM1. 2. Anti-GAD antibody testing is a key diagnostic tool in SPS. 3. Early treatment with symptomatic and immunomodulatory therapies can significantly improve quality of life. Recent studies continue to support the central role of anti-GAD antibodies in SPS, and emerging research is exploring targeted immunotherapies. IVIg has been validated in multiple controlled trials as an effective treatment and may be considered early in the disease course for patients with severe symptoms.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of GCA with loss of vision and asked what to do? (No ESR in the choices)",
    "option_a": "Steroids",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Giant Cell Arteritis (GCA) is an inflammatory vasculitis affecting large and medium-sized arteries, particularly branches of the carotid artery such as the temporal artery. It most commonly occurs in older individuals and is a medical emergency when ocular involvement is present. GCA is characterized by granulomatous inflammation within the arterial wall leading to luminal narrowing and ischemia. This inflammation often results in vessel wall thickening and can compromise blood flow, particularly to the optic nerve, resulting in vision loss. Clinically, patients may present with headache, jaw claudication, scalp tenderness, and systemic symptoms such as fever and weight loss. The most feared complication is acute vision loss in one or both eyes due to ischemic optic neuropathy. In scenarios with visual symptoms, immediate treatment is essential to prevent permanent blindness. Though laboratory tests such as ESR and CRP are typically elevated in GCA, the diagnosis is primarily clinical when ocular symptoms are present. Temporal artery biopsy is the gold standard for diagnosis but should not delay treatment. Differential diagnoses include other causes of vision loss and headaches, such as acute ischemic optic neuropathy from other causes, migraine, or other vasculitides. The first-line treatment is high-dose corticosteroids, often initiated immediately upon clinical suspicion to prevent irreversible vision loss. Intravenous steroids may be indicated for ocular involvement, followed by high-dose oral prednisone with gradual tapering. Pregnancy and lactation considerations: Corticosteroids are generally considered acceptable in pregnancy when the benefits outweigh the risks, though careful monitoring is needed due to potential maternal and fetal side effects. Option A (Steroids) is correct because prompt administration of corticosteroids is the cornerstone of therapy in GCA with visual loss. Other options, if provided, might delay treatment or not address the underlying inflammation promptly, risking permanent vision impairment. 1. Never delay corticosteroid treatment when GCA is suspected, especially with visual symptoms. 2. Temporal artery biopsy can confirm the diagnosis but should not delay treatment initiation. 3. High clinical suspicion in older adults with new headache and visual disturbances warrants immediate therapy. Recent guidelines emphasize the urgency of initiating high-dose corticosteroids in GCA to prevent irreversible vision loss. Studies continue to support early intervention, and there is emerging interest in steroid-sparing agents (e.g., tocilizumab) particularly in patients with relapsing disease, though steroids remain the first-line treatment.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Question about what is true of multiple sclerosis",
    "option_a": "Activation of unmyelinated axons will result in Uhthoff phenomenon",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disorder of the central nervous system characterized by episodes of neurological deficits that can be relapsing-remitting or progressive over time. It is the prototypical demyelinating disease with a diverse clinical presentation. In MS, an autoimmune reaction leads to the destruction of myelin sheaths surrounding axons in the brain and spinal cord. The demyelinated segments become vulnerable to conduction block, particularly in conditions of increased temperature\u2014a phenomenon known as Uhthoff's phenomenon. Importantly, this worsening is related to demyelinated (historically myelinated) fibers; the concept does not apply to unmyelinated axons. Uhthoff phenomenon is a transient worsening of neurologic symptoms in MS patients when body temperature rises (e.g., following exercise, hot baths, or fever). This effect is due to impaired conduction in demyelinated nerve fibers. The misstatement in option A refers to 'activation of unmyelinated axons,' which is incorrect because MS affects myelinated neurons. Diagnosis of MS is based on clinical evaluation, supported by MRI findings of demyelinating lesions in the central nervous system, and sometimes supplemented by cerebrospinal fluid analysis showing oligoclonal bands. Differential diagnoses include neuromyelitis optica, acute disseminated encephalomyelitis, and other demyelinating conditions. Management includes treating acute relapses with corticosteroids and long-term disease-modifying therapies (DMTs) such as interferon beta preparations, glatiramer acetate, fingolimod, natalizumab, ocrelizumab, and others. In pregnancy, certain DMTs (like interferon beta) are used with caution, while others (like fingolimod) are contraindicated. Treatment choices should be tailored after discussing risks and benefits with the patient. Option A is incorrect because Uhthoff phenomenon in MS relates to the conduction block in demyelinated myelinated axons and not due to the activation of unmyelinated axons. The marked answer (Option B) is correct as it likely describes an accurate statement about the disease, aligning with the true pathophysiological mechanisms of MS. 1. Uhthoff phenomenon is an important clinical clue in MS and underscores the temperature sensitivity of demyelinated fibers. 2. MS is a heterogeneous disease; MRI is the cornerstone of diagnosis. 3. A wide range of DMTs is available; tailoring therapy to disease activity and patient profile is essential. Recent research has focused on early intervention with DMTs to delay disability progression in MS. Updated guidelines emphasize personalized medicine and the need for regular monitoring with MRI to assess breakthrough disease. Additionally, emerging therapies continue to expand the treatment landscape for different MS phenotypes.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Lady known to have MS on fingolimod, her brain MRI is showing left frontal new active lesions, what will you do?",
    "option_a": "Continue on fingolimod",
    "option_b": "Interferon",
    "option_c": "Natalizumab",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "In multiple sclerosis (MS), disease-modifying therapies (DMTs) are used to reduce the frequency of relapses and slow disease progression. Fingolimod is a moderate-efficacy agent; however, breakthrough disease indicated by new active lesions on MRI suggests that the current treatment may be insufficient. Breakthrough lesions on MRI indicate ongoing inflammatory activity despite treatment. Fingolimod works by sequestering lymphocytes in lymph nodes to prevent CNS infiltration, but the presence of new lesions implies insufficient immunomodulation. Escalating therapy in such cases aims to more effectively suppress the immune response underlying demyelination. A patient with MS on fingolimod who develops new active lesions is demonstrating subclinical disease activity that may herald clinical relapses or progression. This scenario calls for reassessment of therapeutic efficacy and consideration of escalation to a more potent DMT. Monitoring disease activity in MS involves periodic MRI studies along with clinical evaluations. Differential considerations for new lesions include pseudoprogression or artifacts, but true active lesions are diagnosed based on contrast enhancement and correlation with clinical symptoms. For breakthrough disease on fingolimod, the latest guidelines suggest escalating therapy to a higher efficacy agent. Natalizumab is a well-established high-efficacy DMT indicated for patients with relapsing-remitting MS who have evidence of active inflammatory disease despite treatment. In terms of pregnancy and lactation, fingolimod is contraindicated due to teratogenicity. Natalizumab has been used cautiously in pregnancy when benefits outweigh risks, but requires careful monitoring given its association with progressive multifocal leukoencephalopathy (PML); therefore, JC virus antibody status must be assessed before initiating therapy. Option A (Continue on fingolimod) is not ideal because the emergence of new active lesions indicates treatment failure. Option B (Interferon) is generally less effective in patients who have already failed a moderate-efficacy DMT. Option C (Natalizumab) is correct as it is a high-efficacy agent that can better control disease activity in patients with breakthrough lesions. It offers a robust mechanism to prevent further relapses, provided proper screening for PML risk is performed. 1. New active lesions on MRI in an MS patient signal a need for therapeutic reassessment and possible escalation. 2. Natalizumab, while effective, requires JC virus screening due to PML risk. 3. Early intervention with a higher efficacy DMT can help prevent irreversible neurological damage. Recent clinical trials and long-term observational studies have demonstrated that natalizumab significantly reduces relapse rates and MRI lesion activity in patients with active relapsing-remitting MS. Current guidelines support its use in patients who experience breakthrough disease on moderate-efficacy therapies like fingolimod, emphasizing individualized risk assessment, particularly concerning pregnancy planning and PML risk.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_20.png"
  }
]